Vivosim Labs, INC. annual report, FY2016

Business context and reporting period

The supplied filing is Organovo Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2016, not a Vivosim Labs, Inc. filing. “2015 Q4” does not describe the annual reporting period; the filing also provides unaudited fourth-quarter results. Organovo is an early commercial-stage 3D bioprinting company focused on human tissue models for research and drug development, with therapeutic tissue applications at an early stage. Its first commercial offering, exVive3D Human Liver Tissue, was sold primarily through research services. Human Kidney Tissue was under development. Samsara Sciences, a wholly owned cell-supply subsidiary, began commercial operations in January 2016.

Financial performance and position

FY2016 revenue comprised $806,000 of product and service revenue, $486,000 of collaboration revenue, and $191,000 of grant revenue. The filing reports revenue growth of approximately 150%; the displayed annual totals imply growth of about 160%, so investors may wish to reconcile the stated percentage. Gross profit and gross margin are not separately presented. The company reported no material conventional debt balance; lease obligations were $6.148 million, and capital lease obligations were zero at March 31, 2016.

Financing activities provided $43.452 million in FY2016, principally from a common-stock offering that generated approximately $43.1 million net. The company issued 10.84 million shares in that offering. Investing activities used $2.135 million, mainly for fixed assets. Outstanding shares rose from 81.54 million to 92.39 million during the year. The accumulated deficit was $160.870 million.

For the unaudited fourth quarter of FY2016, revenue was $548,000, net loss was $8.372 million, and basic and diluted loss per share was $0.09.

Changes versus the prior comparable year

• Revenue increased from $571,000 to $1.483 million, driven by more liver-tissue customer contracts, two new research collaborations, and grant activity.
• Operating expenses rose approximately 30% to $40.1 million. Research and development expense increased 40% to $18.0 million; selling, general and administrative expense increased 23% to $22.1 million.
• Net loss widened by approximately $8.5 million, while operating cash use increased by approximately $9.8 million.
• Cash increased by $11.949 million, supported by equity issuance despite higher operating cash use. FY2016 share-based compensation expense was $8.556 million.
• In January 2016, Samsara began commercial operations, supplying cells to Organovo and offering cells to outside customers.

Outlook, commentary, risks and unusual items

Management stated that available cash and its current operating plan were expected to fund the business for at least the next 12 months. It also said additional capital would be needed for longer-term development and commercialization. No numerical revenue or earnings guidance was provided. The company expected continued investment in research, product development, and commercialization and had not achieved significant revenue from its planned principal operations.

• Key risks include ongoing losses and cash consumption; uncertain customer adoption and commercial scalability; competition and rapid technology change; reliance on collaborators and a concentrated early customer base; and the availability, quality, and cost of human cells.
• Therapeutic tissue products would require extensive, lengthy, and uncertain regulatory review. The filing says research-use tissue models were not then subject to known FDA sales requirements, but GLP acceptability had not been independently confirmed.
• The company had no redundant laboratory facilities; its San Diego operations are near active earthquake fault lines. It also identified risks involving intellectual property protection, financing and dilution, and evolving regulatory requirements.
• FY2016 included an unusual stock-compensation charge associated with accelerating vesting and extending the exercise period for a departing employee’s options. Changes in warrant-liability fair value were small in FY2016 but can fluctuate with stock-price assumptions.
• Operating lease commitments totaled $6.148 million. No material legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements and internal controls; management and the auditor concluded internal control over financial reporting was effective as of March 31, 2016.

Important facts for investors to verify

• Confirm the issuer and filing period: this document is Organovo Holdings, Inc.’s FY2016 10-K, not a Vivosim Labs, Inc. filing or a standalone 2015 Q4 report.
• Reconcile the filing’s stated 150% revenue growth with the reported revenue totals of $571,000 and $1.483 million.
• Track revenue composition, liver-tissue contract growth, customer concentration, and whether collaboration and grant income are recurring.
• Assess cash runway against operating cash use of $29.4 million, management’s 12-month liquidity statement, and expected financing needs.
• Review dilution exposure, including equity-plan capacity, outstanding options and warrants, and any future capital raises.
• Monitor kidney-tissue development, Samsara’s external sales, regulatory validation, and evidence of repeatable product economics.